First in Class

On June 18, 2026, F2G and Shionogi announced that olorofim met its primary endpoint in the Phase 3 OASIS trial — 23.8% all-cause mortality at day 42, versus 24.3% for AmBisome followed by standard of care. Non-inferiority confirmed. Drug-related adverse events: 35.8% versus 63.9%.

The numbers are modest. Non-inferiority, not superiority. But here is what they mean: for the first time in over twenty years, a drug with a genuinely novel antifungal mechanism has delivered in a pivotal trial. Olorofim is a DHODH inhibitor — it blocks pyrimidine biosynthesis through a target no approved antifungal has ever touched. It is oral. It overcame a 2023 FDA Complete Response Letter. And it works in a patient population — invasive aspergillosis refractory to azoles — that has almost no options.

If this were the only signal, it would still matter. It wasn't the only signal.

Three signals in one week

Three institutional signals — pharmaceutical, governmental, academic — all arriving within weeks of each other. This is what it looks like when a neglected crisis begins to generate its own infrastructure.

Why now

Because the numbers forced it.

Candida auris reported 7,045 clinical cases in the United States in 2025, up from 6,304 in 2024 and 4,514 in 2023. Ninety-six percent are fluconazole-resistant. The rate of increase has slowed since 2022, but absolute totals keep climbing. Nevada and California account for roughly half. Over half of US states are now reporting cases. In South Africa, C. auris reached 26% of all candidemia during COVID — rising from 17% to 31% in two years, with peaks tracking all four pandemic waves.

And now it has a wastewater early warning signal. Chang et al. showed facility-level monitoring can detect C. auris subclades and resistance mutations 13–143 days before clinical identification, with over 90% genomic concordance. The same surveillance paradigm that transformed antibacterial resistance detection is now extending to fungi.

Meanwhile, the agricultural cross-resistance story keeps expanding. We knew about Aspergillus fumigatus — 15.6% azole resistance globally, two-thirds carrying the TR34/L98H mutation driven by agricultural triazole fungicide exposure. Now Candida tropicalis has been added to the list: agricultural fungicide exposure driving cross-resistance to medical azoles in a second species. The Verweij commentary put it directly: "Using the same types of antifungal chemicals in both farming and medicine is speeding up resistance." The One Health parallel with antibiotics is no longer hypothetical — it's replicating.

What's in the pipeline

When I wrote about fungal resistance in March (Post #12), the pipeline existed mostly as promise. Four months later, several of those candidates have advanced:

This is more activity than the antifungal field has seen in a generation. But zoom out and the disparity remains staggering.

The gap that remains

Fungi share eukaryotic biology with their human hosts. Every target that kills a fungal cell risks damaging a human one. This is why the antifungal arsenal has been confined to four classes for decades — azoles (ergosterol biosynthesis), echinocandins (cell wall), polyenes (ergosterol binding), and flucytosine (nucleic acid synthesis). It's also why olorofim matters: DHODH is the first genuinely new validated target in this space since 2001.

The diagnostic gap is worse. Fungal infections are diagnosed late, treated empirically, and confirmed slowly. There is no fungal equivalent of the rapid AST revolution transforming bacterial diagnostics. Point-of-care C. auris detection barely exists outside reference labs. The Verweij commentary called this "one of the most critical bottlenecks" — you can't steward drugs you can't target.

And the agricultural azole problem has no regulatory solution. The same triazole chemistry protects billions of dollars in crop yields and treats Aspergillus infections in immunocompromised patients. No country has aligned agricultural fungicide authorizations with clinical resistance data. The Verweij group called for this explicitly. Whether any government acts is another question.

Inflection, not arrival

The antibacterial resistance field had its institutional awakening around 2014–2016: the O'Neill Review, the Global Action Plan, the first CARB-X portfolio, the UK subscription pilot. A decade later, the infrastructure exists but the pipeline is still shrinking — 60 projects down from 92, the commercial graveyard expanding.

The antifungal field is now where antibacterials were in roughly 2015. The crisis is documented. The institutional response is beginning. But the gap between recognition and impact is measured in years, and fungi are not waiting.

C. auris was first described in 2009. By 2026, it is in over half of US states. A. fumigatus azole resistance has been documented for twenty years; the agricultural driver has been understood for fifteen. T. indotineae went from first identification to 38% of UK dermatophyte isolates in under five years. The clock started long before the institutions noticed.

Olorofim's Phase 3 success is real. BARDA's scoping is real. Fifty researchers calling for a rewrite of the Global Action Plan is real. These are not symbolic gestures — they are the machinery of a response being assembled. The question is whether it assembles fast enough, or whether the antifungal field follows the antibacterial pattern: a decade of institutional apparatus that never quite catches the pathogen.

First in class. First to deliver. First to survive a CRL and come back with data. Whether olorofim becomes the leading edge of a new era in antifungal medicine or a lone success in an otherwise barren landscape depends on everything that happens next — the NDA filing, the fosmanogepix trials, the BARDA acquisitions, the agricultural policy that no one wants to touch. The inflection point is here. The question is where it bends.